SAN DIEGO—(BUSINESS WIRE)—July 30, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report its unaudited financial results for the second quarterended June 30, 2007 on Monday, August 6, 2007, after the U.S.financial markets close. ACADIA's management will host a conferencecall and webcast on Monday, August 6, 2007, at 5:00 p.m. Eastern Timeto discuss ACADIA's financial results and development programs.
The conference call may be accessed by dialing 866-831-5605 forparticipants in the U.S. or Canada and 617-213-8851 for internationalcallers (reference passcode 21628174). A telephone replay of theconference call may be accessed through August 20, 2007 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 80861306). The conferencecall also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archivedthere until August 20, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief FinancialOfficer
(858) 558-2871
SOURCE: ACADIA Pharmaceuticals Inc.